Upload
truongdung
View
226
Download
0
Embed Size (px)
Citation preview
EPS Co., Ltd.The Clinical Service Provider
2010 Business ReportOctober 1, 2009 to September 30, 2010
Greetings to Shareholders and Investors
EPS Co., Ltd., is expanding its business in Japan and overseas,
focusing on contract research organization (CRO) services, which involve
the outsourcing of all services related to clinical studies.
During the fiscal year ended September 30, 2010, our activities in
Japan included taking over business from Atsuku Corporation in
September 2010 and reinforcing our monitoring business. Meanwhile,
EPS China Co., Ltd., commenced sales in China of influenza diagnosis
kits in January 2010, the first such attempt by the EPS Group.* We
have also announced our participation as an associate developer in
the development program for F351, an oral compound for treatment
of hepatic fibrosis and hepatic cirrhosis under development in China
by GNI Co., Ltd., a Japanese drug-discovery venture company in July
2010. We expect this drug to be a blockbuster, with the markets for it
expected to reach US$2.4 billion in China and the United States and
US$1.9 billion in Japan. We are supporting phase II clinical studies in
China with the goal of commercializing F351 in China and Japan. We
also concluded a master service agreement in China with AnGes MG,
Inc., a bio-venture company in Japan, in July 2010.
We intend to continue such expansion of our business, working in
close coordination with our group companies and partners. We
remain grateful for the kind support of our investors and hope they will
remain with us as we continue to grow.
December 2010
*EPS China obtained a license to wholesale medical devices, as well as an import/export permit, on January 15, 2010, and has since begun to import and sell the influenza preparation kits (called Espline) in China.
Yan Hao, President & CEOYan Hao was born in 1962 in Jiangsu Province, China. In 1979,
he entered the Engineering Department of the University of
Tianjin. In 1981, He came to Japan, where he entered the
University of Yamanashi as a government scholar. After
graduation, he majored in Biometrics and Medical Infomatics at
the University of Tokyo’s graduate studies program and engaged
in research and operation of clinical studies. In 1991, He
established EPS Tokyo, now known as EPS Co., Ltd. In 2001,
its 10-year anniversary, the Company made a successful initial
public offering on the JASDAQ market. In 2006, the Company
listed on the First Section of the Tokyo Stock Exchange Market.
2
The EPS Group is expanding across a broad range of businesses, including CSO, IT and human resource services business centering on CRO and SMO.
EPS Co., Ltd. has established a structure enabling the contracting of all CRO work, from nonclinical studies through post-marketing research. In addition to the development of ethical drugs and post-marketing study practices for pharmaceutical company, EPS supports drug development through bio-ventures and physician-initiated clinical studies. E-Trial Co., Ltd., supports the streamlining of clinical studies through computerization by constructing data collection and management systems utilizing electronic data capturing (EDC).
EP-Mint Co., Ltd. handles clinical studies support for medical institutions. The company has expanded its
business in response to the growing need for such services, and is now one of the largest Japanese SMOs in terms of its number of clinical research coordinators (CRCs) and branch offices in Japan. The company aims to become Japan’s leading SMO by maximizing the advanced skills and extensive trial site experience of its clinical research coordinators, as well as further enhancing its internal structure.
Domestic medical services
Overseas medical services
EPS International Co., Ltd., is expanding its CRO business in Shanghai, Beijing, Hong Kong, Taipei, Seoul Singapore. The company has established a system designed to handle the growing number of international joint clinical studies conducted in Asia. EPS China Co., Ltd., the umbrella organization for the EPS Group’s business in China, is making progress inenhancing its system for contracting data center
Support for clinical studies by pharmaceutical companies
CRO business
Support for clinical studies at medical institutions
SMO business
Expanding CRO business in Asia
CRO business
An introduction to the EPS Group
3
Preclinical study agency business and import/sales of related materials
Preclinical study
Highly specialized call center services
Call center servicesFocusing on IT services for the medical and healthcare industries
Software development business
Providing temp staff for CSO and CRO business
Temp staff dispatching
work and medical IT system planning, construction and operations. EPS China Co., Ltd. continuously invests in medical products business areas in China new to the EPS Group, while keeping a sufficiently close eye on risk.
All Right Software Co., Ltd. conducts software development. In addition to its business solution services, such as the dispatch of IT technicians and provision of teleconferencing systems, the company
focuses on IT services, such as testing support, for the medical and healthcare industries.
LSG Co., Ltd. offers a variety of overseas agency services to preclinical studies using laboratory animals to examine scientific properties and side effects. Henceforth, LSG Co., Ltd. will focus on expanding the market for purified diet for use at university facilities, as well as on contracting for safety studies, including bio-safety studies.
Pharma Network Co., Ltd. conducts CSO business. The company aims to expand its operations by contracting for MR work, dispatching MR staff and conducting MR training. EP-Mate Co., Ltd. is in the business of dispatching pharmaceutical development experts, and will continue to strengthen its business profile.
Medical Line Co., Ltd. provides highly specialized call center services staffed by expert pharmacists for the medical, pharmaceutical and healthcare industries. The company seeks to expand its business by maximizing its synergies with our Group companies.
IT services
Human resource services
An introduction to the EPS Group
4
EPS Group
Providing full-service in drug development contracts September 30, 2010
Business CRO CRO(pre-clinical)Company SMO Human
resources IT Drugdis-cover
Callcenter
■ Established year / 1991■ CEO / Yan Hao ■ Employees / 1,288
■ Established year / 1999■ CEO / Shinro Tashiro■ Employees / 444
■ Established year / 2006■ CEO / Satoru Kono■ Employees / 25
■ Established year / 2007■ CEO / Tatsuhiko Ichiki■ Employees / 128
■ Established year / 2002■ CEO / Takeshi Tadano■ Employees / 109
■ Established year / 1997■ CEO / Makoto Enokido■ Employees / 237
■ Established year / 2005■ CEO / Yasuo Kiba■ Employees / 63
■ Established year / 2006■ CEO / Junichi Nishizuka■ Employees / 204
■ Established year / 2001■ CEO / Yan Hao■ Employees / 217
■ Established year / 2008■ COO / XIA XiangMing■ Employees / 84
Domestic drug service
Overseas drug service
Human resources service
IT service
Chinese business
The numbers of employees are excluded temporary and contracted staff.
5
Answering your questions regarding EPS Group servicesThe core mission of the EPS Group is our CRO business, which involves multifunctional support such as SMO business, preclinical study business, and CSO work related to MR staff dispatch. We support product development conducted by pharmaceutical companies through our groupwide structure, which provides full drug development support, from planning through the filing of new drug applications. The following are answers to frequently asked shareholder and investor questions.
Q&ASpecial Issue
Drug development is a serious burden for
pharmaceutical companies, involving long
time periods and ever-expanding costs. Clinical
studies are necessary for drug development, but they
also are burdensome to medical institutions, which
must devote resources to treating patients while
simultaneously cooperating in drug testing.
Companies therefore outsource drug study work, and
contract research organizations (CROs) and site
management organizations (SMOs) provide that
outsourcing support.
Pharmaceutical companies contract CROs to
perform clinical studies. SMOs contract with medical
institutions to support the work conducted by
physicians and nurses in clinical studies. Within the
EPS Group, EPS Co., Ltd. conducts CRO business for
pharmaceutical companies that develop new drugs,
while EP-Mint Co., Ltd., conducts SMO business for
medical institutions that conduct clinical studies of the
new drugs. Operating these businesses through
separate companies ensures the reliability of the data
and guarantees independence and fairness.
The EPS Group supports a wide range of
drug development. We have particularly
extensive experience in oncological, cardiovascular
and central nervous system medicine, which treat the
three major causes of death in Japan.
A
A
Q How do CROs and SMOs differ?
Q In which areas of drug developmentis the EPS Group involved?
Knowing it and getting it !
6
The Number of Protocols (By Therapeutic Areas)
500
400
300
200
100
0
Oncology
Cardiovascular
Central Nervous System
Endocrine/Metabolic
Musculus/Bones
Sensory Organs
Gastrointestinal
Hematology
Infections
Urology
Imm
unology/Allergies
Respiratory
Others
100
234 213 213
895872818386
136
267
453
We have also announced our participation in F351,
which is under development by GNI Co., Ltd. in China.
F351 is an oral compound for treatment of hepatic
fibrosis and hepatic cirrhosis. Following China and
Australia, in 2010 patents were obtained in Canada,
the United States and Japan. We aim to
commercialize F351 as a blockbuster drug in China
and Japan, and are providing our support as an
associate developer in GNI’s clinical studies.
We lay out the framework for full support,
from basic and preclinical studies through
post-production and marketing surveys. Additionally,
the Group companies each focus on a particular area
EPS International Co., Ltd. was established in
2007 to meet clinical studies needs in Asia.
The company offers comprehensive CRO services
based in Shanghai, Beijing, Hong Kong, Taipei, Seoul
and Singapore. EPS China was established in 2008 in
Suzhou to strengthen our overseas businesses and
support high-quality clinical studies internationally.
EPS China Co., Ltd. commenced sales of influenza
diagnosis kits in January 2010 (see page 2). This
represents our first foray into sales of material
products, and we hope to contribute to developing the
medical industry in China through this effort.
of the drug development process, such as SMO, CSO,
personnel services, preclinical study business and
system development. Our efficient work system based
on our rich knowhow and wealth of experience
contributes to speeding up the drug development
process, from the development stage through
approval. The EPS Group’s unique strength lies in our
ability to offer high quality customer service
customized to meet pharmaceutical company and
medical institution needs. Stronger demand for
outsourcing of clinical studies in Asia provides a critical
boost to us in our Asia-centered global operations.
A
Q What are the advantages of a full support system for clinical development?
Q Describe your overseas business progress.
A
7
Operating Income(Millions of yen)
Net Sales(Millions of yen)
■Non-consolidated ■Consolidated
0 5,000 10,000 15,000 20,000 25,000 30,000
18th TermFY9/08
19th TermFY9/09 17,980 23,568
15,403
20th TermFY9/10
■Non-consolidated ■Consolidated
18th TermFY9/08
19th TermFY9/09
20th TermFY9/1017,980 29,451
17,948
21,182
13,108
0 1,000 3,0002,000 5,0004,000
3,487
2,442
4,008
3,347
4,415
3,922
8
●CRO businessOur CRO business is handled mainly by EPS Co., Ltd.
The Clinical Development Division’s monitoring business continued to perform favorably in terms of existing and new orders for clinical studies at the development and post-production and marketing stages, chiefly for anticancer, diabetes, high blood pressure and central nervous system (CNS) drugs.
The Biometrics Division vigorously pushed forward in both existing projects and new project acquisition for its data management, statistical analysis, medical writing, pharmacovigilance, and registration and project management services. As a result, revenues from these services increased over the preceding fiscal year.
Our Data Center services, which mainly involve post-marketing studies and drug performance surveys, remained strong.
The Clinical Coordination Center, which provides new business planning and other services associated with medical device development, carried out existing projects and acquired new projects. Consequently, year on year earnings for these services increased.
As described above, the earnings of the Company remained steady, with sales at each division increasing over the previous consolidated fiscal year. In addition, our cost reduction efforts led to increases in nonconsolidated sales and profits over the preceding fiscal year.
At our domestic consolidated subsidiaries, sales and profits at e-Trial Co., Ltd., rose in comparison to the previous fiscal year due to its continued efforts to acquire new contracts for clinical studies based on the EDC system of electronically accumulating and managing the results of clinical studies. EPMate Co., Ltd., engaged in staff dispatching services (CRO
Management Results
Business Trends
Net Income per Share(Yen)
Net Income(Millions of yen)
0 800 1,6001,200400 2,000 2,400
■Non-consolidated ■Consolidated
18th TermFY9/08
19th TermFY9/09
20th TermFY9/10
■Non-consolidated ■Consolidated
18th TermFY9/08
19th TermFY9/09
20th TermFY9/10
0 10,0005,000 15,000 20,000
1,708
1,360
1,713
1,583
2,191
2,252
19,110
15,220
19,162
17,715
12,255
12,596
9
dispatching business) for pharmaceutical companies, achieving substantial increases in sales and profits compared with a year earlier thanks to growth in its dispatched monitoring service. Pharma Network Co., Ltd., a provider of such CSO services as MR dispatching, merged with EP Medical Co., Ltd., in October 2009, resulting in sharply increasing year on year sales. Nonetheless, profits decreased as the company concentrated its efforts on streamlining its corporate structure.
Medical Line Co., Ltd., which became a consolidated subsidiary in October 2009, is engaged in dispatching personnel such as pharmacists particularly to the medical, pharmaceutical and healthcare industries, as well as in information provision services. Its earnings increased over the previous fiscal year due to a rise in sales of its mainstay drug information (DI) service and the strong performance of the contact center service,
involving campaigns to enhance public awareness of diseases. Profits of Medical Line began contributing to consolidated earnings during the fiscal year.
In the overseas CRO business, EPS International Co., Ltd. and its group companies, which EPS International (China) Co., Ltd., EPS Singapore Ltd. and EPS Hong Kong Ltd., did their utmost to obtain new orders for CRO services relating to cross-border clinical studies, especially in Asia.
Continuing from the previous fiscal year, EPS China Co., Ltd. proceeded to make preparations for full-scale data management, drug discovery and medical IT operations.
As a result, sales and profits of the CRO business for the fiscal year under review increased compared with previous year, with consolidated net sales reaching ¥23,143 million, up 32.1%, and operating income standing at ¥3,958 million, up 11.6%.
■Interim ■Annual (Yen)
0
2,000
4,000
6,000
8,000
FY9/09 FY9/10
2,800
3,200
FY9/11 Budget
3,200
1,900
1,900
1,600
6,0005,100
3,500
10
●SMO business EP-Mint Co., Ltd., which conducts SMO business, enhanced its branch-based management system in working to acquire new orders, focusing on CRC service as well as site-support services such as the clinical study administration in cooperation with local trial sites. Consequently, both sales and profits of the SMO business for the fiscal year rose compared with previous year, with consolidated net sales totaling ¥4,058 million, up 21.2%, and operating income standing at ¥606 million, up 21.0%.
●Preclinical study businessThe preclinical study business, which is conducted by the LSG group, was adversely affected by excessive supply in the market for laboratory animals. As a result, sales and profits of the preclinical study business for the fiscal year declined sharply compared with previous year, with consolidated net sales registering ¥860 million, down 18.4%, and operating income standing at ¥6 million, down 87.7%.
●Software development businessThe software development business is conducted by the All Right Software Group. The visual communication business centering on videoconferencing systems was strong as companies increasingly cut back on overseas business trips while beginning to use videoconferencing. Meanwhile, the mainstay software development business was hit by
Management Results
the economic recession. Consequently, consolidated net sales of the software development business for the fiscal year under review were ¥1,549 million, down 11.6%, and the operating loss was ¥163 million, compared with a loss of ¥100 million of previous year.
The above consolidated net sales and operating performance by business segment include inter-segmental transactions. After deducting these transactions, overall sales and profits for the fiscal year under review increased over the previous fiscal year. Consolidated net sales amounted to ¥29,451 million, up 25.0% year on year. Operating income was ¥4,415 million, up 10.2%, ordinary income stood at ¥4,443 million, up 9.7%, and net income was ¥2,191 million, up 27.9%.
DividendsWe decided to pay an annual dividend of ¥5,100 per share for the fiscal year ended September 2010 (20th term), comprising ¥3,200 as a second-quarter dividend and ¥1,900 as a year-end dividend. We conducted a 2-for-1 stock split, with March 31, 2010 as the record date. We are grateful to our shareholders for their continued support.
11
CURRENT ASSETS
Cash and cash equivalents
Notes and accounts receivable
Inventories and products
Works in progress
Deferred tax assets
Others
Allowance for doubtful accounts
Total current assets
FIXED ASSETS
Tangible Assets ;
Leasehold improvements
Accumulated depreciation
Furniture and fixtures
Accumulated depreciation
Others
Accumulated depreciation
Total property and equipment
Intangible Assets ;
Goodwill
Others
Total intangible assets
Investments and other assets ;
Investment securities
Deposits
Time deposits and banking arrangements other than cash equivalents
Deferred tax assets
Others
Total investments and other assets
Total fixed assets
TOTAL ASSETS
7,956,839
5,954,040
317,270
337,675
934,367
561,586
(6,459)
16,055,320
521,652
(265,275)
513,181
(325,510)
391,680
(121,707)
714,020
597,949
242,490
840,439
585,816
1,179,445
500,000
304,854
470,742
3,040,858
4,595,318
20,650,639
6,607,331
5,211,905
231,824
253,598
645,892
494,226
(2,108)
13,442,670
444,596
(224,094)
385,317
(252,448)
167,856
(76,061)
445,165
159,358
204,830
364,189
881,700
1,012,144
500,000
314,360
346,629
3,054,836
3,864,190
17,306,861
ASSETS
(Thousands of yen)Consolidated Balance Sheets
Financial Information
(Thousands of yen)
CURRENT LIABILITIES
Accounts payable
Short-term debt
Current portion of long-term debt
Income taxes payable
Provision for bonuses
Provision for loss on order received
Others
Total current liabilities
LONG-TERM LIABILITIES
Provision for employee's retirement benefits
Provision for director's retirement benefits
Others
Total long-term liabilities
TOTAL LIABILITIES
Shareholders' equity
Common stock
Additional paid-in capital
Retained earnings
Common stock for treasury
Total shareholders' equity
Valuation and translation adjustments
Unrealized gain (or loss) on available-for-sale securities
Deferred gain (or loss) on hedges
Foreign currency translation adjustments
Total valuation and translation adjustments
Share option in consolidated subsidiary
Minority interests
TOTAL NET ASSETS
TOTAL LIABILITIES AND NET ASSETS
LIABILITIES
NET ASSETS
September 30,2009
September 30,2010
September 30,2009
September 30,2010
204,226
150,000
200,000
944,772
1,145,169
75,650
1,899,275
4,619,093
307,137
247,397
25,378
579,912
5,199,006
1,875,251
1,825,431
7,657,862
(321,437)
11,037,108
(39,782)
(2)
(65,647)
(105,431)
1,176,178
12,107,854
17,306,861
238,683
185,000
1,353,483
1,443,761
145,000
2,253,900
5,619,828
364,582
279,874
39,090
683,547
6,303,376
1,875,251
1,826,300
9,277,109
(317,258)
12,661,403
(946)
(115,922)
(116,869)
6,528
1,796,201
14,347,262
20,650,639
For the years ended September 30, 2010
For the years ended September 30, 2009
For the years ended September 30, 2010
For the years ended September 30, 2009
NET SALESCOST OF SALES
Gross profitSELLING, GENERAL AND
ADMINISTRATIVE EXPENSESOperating income
OTHER INCOME (EXPENSES)Interest incomeInterest expensesGain on cancellation of life insurance Service fee incomeGain or loss of equity in associated
companies (loss)Gain on sales of property and equipmentForeign exchange gain or loss (loss)Dividends incomeGain on sale of investment securitiesGain on change in equity by merger
of consolidated subsidiaryRefund of insurance surrender Subsidy in consolidated subsidiariesLoss on sales and disposal of
property and equipmentLoss on devaluation of investment
securitiesImpairment loss on goodwillOthers- net
Other income (expenses)-net
Income before income taxes and minority interests
INCOME TAXES CurrentDeferred
Total
MINORITY INTERESTS
NET INCOME
23,568,50316,031,681
7,536,821
3,528,477
4,008,344
25,570(9,720)6,1325,829
5,107
697(7,446)7,675
53,695
---
(28,583)
(173,746)
(125,666)(14,843)
(255,298)
3,753,045
1,729,771219,840
1,949,61190,283
1,713,150
29,451,04619,970,311
9,480,734
5,065,531
4,415,203
17,890(8,782)
22,1976,108
9,999
-(40,008)
5,187288
34,961
25,32023,660
(17,382)
(284,141)
(10,000)5,195
(209,505)
4,205,698
2,156,891(249,539)
1,907,352106,939
2,191,407
Consolidated Statements of Net Assets (Thousands of yen)
Shareholders' equity
Common stock
Additional paid-in capital
Retained earnings
Common stock for treasury
Valuation and translation adjustments
Unrealized gain (or loss) on available-for-sale securities
Deferred gain (or loss) on hedges
Foreign currency translation adjustments
Share option in consolidated subsidiary
Minority interests
TOTAL NET ASSETS
11,037,108
1,875,251
1,825,431
7,657,862
(321,437)
(105,431)
(39,782)
(2)
(65,647)
-
1,176,178
12,107,854
12,661,403
1,875,251
1,826,300
9,277,109
(317,258)
(116,869)
(946)
-
(115,922)
6,528
1,796,201
14,347,262
Consolidated Statements of Income(Thousands of yen)
Financial Information
12
For the years ended September 30, 2010
For the years ended September 30, 2009
For the years ended September 30, 2010
For the years ended September 30, 2009
Consolidated Statements of Cash Flows(Thousands of yen)
OPERATING ACTIVITIES:
Income before income taxes and minority interests
Adjustments to reconcile income before income taxes and minority interests to net cash provided by operating activities:
Depreciation and amortization
Impairment loss on goodwill
Increase (Decrease) in provision for bonuses
Increase (Decrease) in allowance for retirement benefits for employees
Increase (Decrease) in allowance for retirement benefits for directors
Interest and dividends income
Interest expense
Gain (or loss) on sale of investments in securities (-net)
Loss on devaluation of investments in securities
Gain (or loss) on sales and disposal of property and equipment (-net)
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable-trade
Decrease (increase) in inventories and products
Increase (decrease) in accounts payable -trade
Increase (decrease) in other current liabilities
Others, Net
Subtotal
Interest and dividends received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
3,753,045
272,090
125,666
60,924
24,922
38,336
(33,246)
9,720
(51,960)
173,746
27,886
(621,311)
55,143
(15,320)
119,948
(8,251)
3,931,339
36,683
(9,720)
(1,895,528)
2,062,773
4,205,698
429,650
10,000
299,521
17,334
13,371
(23,078)
8,782
(288)
284,141
17,382
(492,149)
(183,056)
(325)
175,321
(29,867)
4,732,440
25,919
(8,782)
(1,745,892)
3,003,684
--
(162,555)
(42,697)
(239,339)
560,892
(187,968)
(75,400)(213,753)
-
72,975
10,253
(277,594)
--
(205,700)
9,942
(519,428)(31,661)
(3,923)
(750,770)
(66,062)
968,346
5,638,984
-
6,607,331
(203,298)202,937
(360,948)
(112,729)
-
-
(169,577)
(86,008)(71,000)
(402,041)
-
27,051
( 1,175,614)
220,000
(215,000)
(200,000)
-(572,084)
(18,078)(21,642)
(806,805)
(28,215)
993,049
6,607,331
205,600
7,805,981
INVESTING ACTIVITIES:Payments for time depositsProceeds from maturity of time depositsDisbursements for purchase of
tangible fixed assets Disbursements for purchase of
intangible fixed assets Payment for purchase of investments
securities Proceeds from sales and maturity of
investment securitiesPayment for deposit for rent office
and othersPayment for insurance reserve fundPayments for acquisition of businessPurchase of investments in subsidiaries
resulting in change in scope of consolidation
Proceeds from purchase of investments in capital of subsidiaries resulting in change in scope of consolidation
Others , Net Net cash provided by (used in)
investing activitiesFINANCING ACTIVITIES:
Proceeds from borrowing short-term debt Disbursements for repayment of
short-term debt Disbursements for repayment of
long-term debtProceeds from capital increase by
minority stockholdersDividends paidDividends paid to minority stockholdersOthers , NetNet cash provided by (used in)
financing activitiesEFFECT OF EXCHANGE
DIFFERENCE ON CASH & CASH EQUIVALENTS
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
BEGINNING OF BALANCE, CASH AND CASH EQUIVALENTS
INCREASE IN CASH AND CASH EQUIVALENTS BY MERGER OF CONSOLIDATED SUBSIDIARY
ENDING OF BALANCE, CASH AND CASH EQUIVALENTS
(Thousands of yen)
13
14
(Thousands of yen)
(Thousands of yen)
Industry Segment2010 (October 1, 2009 to September 30, 2010)
2009 (October 1, 2008 to September 30, 2009)
CRO SMO PreclinicalService
SystemDevelopment Total Eliminations/
Corporate Consolidation
CRO SMO PreclinicalService
SystemDevelopment Total Eliminations/
Corporate Consolidation
23,118,092
25,627
23,143,719
19,184,884
3,958,835
4,056,466
2,265
4,058,731
3,452,266
606,465
856,054
4,140
860,194
853,460
6,733
1,420,433
129,465
1,549,899
1,713,029
(163,130)
29,451,046
161,498
29,612,544
25,203,640
4,408,904
(161,498)
(161,498)
(167,797)
6,298
29,451,046
29,451,046
25,035,842
4,415,203
17,503,999
21,130
17,525,130
13,977,526
3,547,603
3,347,671
3,347,671
2,846,638
501,032
1,050,321
4,140
1,054,461
999,899
54,562
1,666,510
86,941
1,753,451
1,854,288
(100,836)
23,568,503
112,211
23,680,715
19,678,353
4,002,362
(112,211)
(112,211)
(118,194)
5,982
23,568,503
23,568,503
19,560,159
4,008,344
SALES
Sales to customers
Intersegment sales
Sales total
Operating expenses
Operating income
SALES
Sales to customers
Intersegment sales
Sales total
Operating expenses
Operating income
Financial Information
648,000
180,800
3,278
33,520
20,536
13,771
13,090
7,068
6,461
5,600
5,435
4,745
3,240
Principal Shareholders
18.53
11.35
7.61
7.24
3.90
3.57
3.09
3.00
2.62
1.79
取締役および監査役 (2010年9月30日現在)
Authorized shares
Shares of common stock issued
Number of shareholders
Shareholder Shares heldPercentage
of total
Shareholder Breakdown
Other Japanese corporations 19.00%34,367 shares, 25 shareholders
Foreign shareholders 32.34%
58,485 shares, 106 shareholders
Securities companies 1.21%
2,198 shares,17 shareholders
Individuals/Others 28.26%
51,102 shares, 3,101 shareholders
Government and local authorities 0.00%
12 shares, 1 shareholders
Treasury stock 1.09%
1,974 shares
Other Japanese financial institutions 18.06%
32,662 shares, 27 shareholders
15
Stock Information (As of September 30, 2010)
Members of the Board and Statutory Auditors (As of September 30, 2010)
President & CEO
Directors
Statutory auditors
Yan Hao
Tatsuhiko Ichiki
Koichi Jingu
Yasuharu Tamai
Hidetaka Ando
Hiroaki Abe
Masaaki Anzai
Kozo Okunaga
Koichi Shibuya
The paper used in this pamphlet is produced from fiber sourced from well-managed forests and other forests where unacceptable sources have been excluded, as defined by the FSC. The printing processes that are used do not involve the output of wastewater.
Company ProfileLocations: Center Office
Tsuruya Bldg. 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo 162-0822TEL: +81-3-5684-7801
Annex. 1Sumitomo Fudosan Iidabashi Bldg. No.42-3-19 Koraku, Bunkyo-ku, Tokyo 112-0004
Annex. 22, 3, 4, 5F, Iidabashi MF Bldg.1-1 Shinogawamachi, Shinjuku-ku, Tokyo 162-0814
Annex. 36F, Daiichikangin Inagaki Bldg.2-1 Shimomiyabicho, Shinjuku-ku, Tokyo162-0822
Annex. 42F, S&S Bldg.6-36 Shinogawamachi, Shinjuku-ku, Tokyo 162-0814
Osaka Branch9, 11F, Nissei Shin-osaka Bldg.3-4-30 Miyahara, Yodogawa-ku, Osaka 532-0003
Nagoya Branch4F, Horiuchi Bldg.3-25-9 Meieki, Nakamura-ku, Nagoya-shi, Aichi 450-0002
EPS Co., Ltd.The Clinical Service Provider
Corporate Name:
President & CEO:
Establishment:
Capital:
Main Services:
E-Mail:
URL:
EPS Co., Ltd.
Yan Hao
May 1991
¥1875.25 million
CRO business and system development
http://www.eps.co.jp/en/index.html
Forward-Looking Statements
The items in this report include descriptions of future plans and forecasts. Actual performances may differ substantially due to various factors.